More importantly, GLTSCR1 deficiency decreased sensitivity to bromodomain and extra terminal domain (BET) inhibitors, which exhibit therapeutic activity in many types of cancer.14 Finally, MSI mutation or expression of GLTSCR1 could be considered as a biomarker of BET inhibitor response for precision therapy in CRC. This evidence concerns the gene BICRA and colorectal carcinoma.